Research Communication: Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education

Aliment Pharmacol Ther. 2025 Jul;62(2):204-207. doi: 10.1111/apt.70197. Epub 2025 May 14.

Abstract

Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.

Publication types

  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents* / administration & dosage
  • Budesonide* / administration & dosage
  • Budesonide* / adverse effects
  • Budesonide* / therapeutic use
  • Eosinophilic Esophagitis* / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Education as Topic
  • Retrospective Studies
  • Tablets
  • Treatment Outcome
  • Young Adult

Substances

  • Budesonide
  • Tablets
  • Anti-Inflammatory Agents